InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025)

InMed Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $70000.0 in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $70000.0; the trailing twelve-month figure through Dec 2025 stood at $112408.0 (changed N/A YoY), and the FY2025 full-year result was $208737.0, down 31.74% from the prior year.
• Asset Writedowns and Impairment for Q4 2025 stood at $70000.0, down from $208737.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $576772.0 in Q3 2022, with the low at -$551687.0 in Q1 2023.
• Historically, Asset Writedowns and Impairment has averaged $78915.5 across 4 years, with a median of $81465.0 in 2023.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment sank 83.89% — and 2025, when it jumped 392.21%.
• InMed Pharmaceuticals' Asset Writedowns and Impairment stood at $576772.0 in 2022, then plunged by 70.44% to $170474.0 in 2023, then slumped by 75.12% to $42408.0 in 2024, then soared by 65.06% to $70000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $70000.0 (Q4 2025), $208737.0 (Q2 2025), and $42408.0 (Q2 2024), per Business Quant data.